Home>Topics>Stocks>Theravance

Theravance THRX

  1. All
  2. Commentary
  3. Headlines
    1. From Barron’s, September 29, 2014 (Part 2)

      Commentary

      Sat, 27 Sep 2014

      BABA ; sell puts as options on BABA start to trade on Monday; pg 20]; Apple [ AAPL ; pg 20]. Bearish stories: Theravance [ THRX ; pg 14]; agricultural sector [machinery AGCO, CNHI, DE ; fertilizer AGU, CF, MOS, POT ; seeds/chemicals

    2. From Barron’s, July 28, 2014 (Part 2)

      Commentary

      Sat, 26 Jul 2014

      even become a SIFI ; its bank has had the top 5-yr CD rate for months ; pg 13]; Dow Chemical [ DOW ; pg 16]; Theravance [ THRX ; COPD drug royalty based company after the spinoff of R&D arm TBPH ; it sells COPD drugs through GSK ; pg 18

    3. FDA panel votes in favor of approval of Glaxo lung drug Anoro

      Headlines

      Tue, 10 Sep 2013

      WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc and Theravance Inc to treat chronic...

    4. Safety data on Glaxo COPD drug inconclusive -FDA staff

      Headlines

      Fri, 6 Sep 2013

      Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive,...

    5. Elan Transformation Continues, but We Remain Skeptical of Deal Values

      Commentary

      Mon, 20 May 2013

      proposed new business deals, and we're maintaining our fair value estimate as we digest the news in relation to last week's Theravance deal announcement. We're intrigued by Elan's decision to take a page out of Valeant's playbook, focusing on underpenetrated

    6. The Benefits of Diversifying the Funding of a Gold Position

      Headlines

      Fri, 17 May 2013

      Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share

    7. Elan's Theravance Deal Creates Passive Stake in Respiratory Disease; We Await Additional Deals

      Commentary

      Mon, 13 May 2013

      Elan ELN has announced that it intends to pay $1 billion to Theravance for a 21% stake in its royalty stream from partner GlaxoSmithKline ..... The deal relates to four of the six programs included in Theravance 's 2002 LABA partnership with Glaxo: Relvar Ellipta/Breo

    8. UPDATE 3-US FDA approves Glaxo/ Theravance drug for COPD lung disease

      Headlines

      Fri, 10 May 2013

      * Drug will compete with AstraZeneca's Symbicort (Updates with FDA comment, side effects)

    9. UPDATE 4-US FDA advisory panel backs Glaxo/ Theravance lung drug

      Headlines

      Wed, 17 Apr 2013

      * Panel votes Breo effective in treating airflow obstruction

    10. FDA panel recommends approval of Glaxo/ Theravance lung drug

      Headlines

      Wed, 17 Apr 2013

      April 17 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve an experimental treatment for smoking-related lung damage made by...

    « Prev12345Next »
    Content Partners